FridayApr 20, 2012 11:52 am

Skinvisible, Inc. (SKVI) Penetrates Multiple Dermatology and Healthcare Product Segments, Driven by Strength of Invisicare IP Platform

Skinvisible is the developer of an advanced family of patented polymer delivery technologies with deep impact into multiple segments ranging from prescription dermatology and over-the-counter skincare products, to hospital-related and consumer goods products for a variety of medical conditions. This delivery platform is known as Invisicare® and SKVI operates through its wholly-owned subsidiary, Skinvisible Pharmaceuticals, Inc., as an R&D-focused pharmaceutical developer. Because the delivery system is so powerful, treatments spanning the gamut, from acne, eczema, warts, and dermatitis, to skin cancer, anti-inflammatory, anti-aging, anti-fungal, hand sanitization, sunscreen, pre-surgical prep, and a whole host of other applications are within striking distance.…

Continue Reading

FridayApr 20, 2012 11:51 am

AL International, Inc. (JCOF) Names New Chief Financial Officer

AL International is a fast-growing diversified company that offers a wide range of consumer nutritional and lifestyle products and services, primarily through person-to-person selling relationships. The company is also a vertically integrated producer of gourmet coffees for the commercial, retail, and direct sales channels. The company announced today that it has appointed Dave Briskie as chief financial officer. Mr. Briskie replaces former CFO Chris Nelson who is no longer with the company. He will also continue to serve in his current roles with AL International as its president of commercial development, chairman of the audit committee, and as a member…

Continue Reading

FridayApr 20, 2012 11:36 am

Advance Cell Technology, Inc. (ACTC) Completes Treatment of Third Dry AMD Patient in Phase I/II Clinical Trial

Advanced Cell Technology, a biotech company focused on the field of regenerative medicine, today reported the successful completion of the dosing of the third patient in its phase I/II trial for dry age-related macular degeneration (AMD) using retinal pigment epithelial (RPE) cells from human embryonic stem cells (hESCs). The company has already conducted the procedure in six other patients at UCLA, and said it anticipates adding more sites in the near future. Gary Rabin, chairman and CEO of ACT, also noted the prestige of individuals participating in the trials. "The completion of enrollment of the first cohort of patients in…

Continue Reading

FridayApr 20, 2012 8:29 am

Rosetta Genomics, Ltd. (ROSG) Receives European Patent for miR-34a Use in Preparing Pharmaceuticals to Treat p53-Negative Cancers

Rosetta Genomics announced today that it has received a grant from the European Patent Office for a patent claiming the use of miR-34a for the preparation of pharmaceuticals to treat p53-negative cancers. A core element of Rosetta Genomics’ microRNA technology in the development of p53-negative-related cancer therapeutics is covered in the issued claims. The patent is owned jointly with Yeda, a technology transfer company of the Weizmann Institute of Science in Rehovot, Israel. The p53 protein, a sequence-specific transcription factor, functions as a major tumor suppressor in mammals. One of the most frequent genetic alterations in human cancer is the…

Continue Reading

ThursdayApr 19, 2012 3:58 pm

Rockwell Diamonds, Inc. (RDIAF) Issues Update on Mining Activities and Corporate Strategy

Rockwell Diamonds reported a strategic and operational update on the company’s recent mining activities. The company owns an interest in three producing diamond mines in South Africa. Rockwell Diamonds is ramping up production at the Tirisano mine and expects this mine to be operating at full capacity by the end of July 2012. The company recently approved an equipment upgrade at Tirisano that will enable the company to deal with production problems associated with wet ores. Rockwell Diamonds reported strong growth in carat production at the Saxendrift mine, with year-over-year production rising by 50%. The company attributed the gain to…

Continue Reading

ThursdayApr 19, 2012 2:46 pm

Location Based Technologies, Inc. (LBAS) Forms Strategic Partnership with West Coast Customs

Location Based Technologies Inc. (LBT), designer and developer of locator devices, today announced it has entered into a strategic partnership with West Coast Customs® (WCC), a luxury automotive restyling center with franchise operations worldwide. PocketFinder GPS easily attaches to any powered vehicle and allows the user to accurately locate their vehicle, and those in it, at any time and from almost anywhere in the world. Per the agreement, PocketFinder Vehicle® GPS devices will be installed into the WCC’s custom automobiles. “LBT is proud to be chosen as West Coast Customs’ preferred in-vehicle GPS solution,” Dave Morse, CEO of LBT stated…

Continue Reading

ThursdayApr 19, 2012 12:26 pm

Palatin Technologies, Inc. (PTN) Announces Start of Second Phase I Trial of Its Obesity Compound

Palatin Technologies is a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with unmet medical needs and significant commercial potential. Obesity is also a focus of the company. Palatin Technologies reported today that a second Phase I clinical trial of AZD2820 has begun with the dosing of the first patient. The compound is administered under the skin and is a peptide melanocortin receptor partial agonist which is under development for treating obesity. The compound is a clinical candidate selected by European drug firm AstraZeneca (NYSE: AZN) from a collaborative research program with Palatin Technologies. AstraZeneca has…

Continue Reading

ThursdayApr 19, 2012 12:25 pm

SPI Solar, Inc. (SOPW) Inks MOU with Taneo Fund to Build 23MW of Solar Projects across Greece

SPI Solar, a leading vertically integrated photovoltaic (PV) solar developer, today announced that it has entered into a memorandum of understanding (MOU) with two fund management companies to develop utility-scale solar energy facilities (SEF) across Greece. Thermi-Taneo Venture Capital Fund and AIMS-Taneo Fund are part of the New Economic Development Fund called the Taneo Fund, a Greek-state sponsored, privately funded and independently managed fund-of-funds focused on venture-capital investments in Greece and Europe. The MOU greatly enhances SPI’s opportunity to triple its development projects across Greece. “We are very pleased to have this agreement in place. It represents a significant opportunity…

Continue Reading

ThursdayApr 19, 2012 12:06 pm

Shelron Group, Inc. (SRNG) Moves to Secure Six Key Licenses on Prime Gold Exploration Acreage in Northern Chile

NY-headquartered mineral E&D (emphasis on gold and copper) company Shelron Group, which is primarily focused on rigorously analyzing and identifying key acquisition targets in Africa/South America, announced today that its newly formed subsidiary, Serena Gold, LLC, has signed a binding memorandum of understanding to acquire prime territory in Northern Chile via six (1,800) gold exploration licenses. This cherry little patch of land has stunning geological analogs, with the nearest being the producing Carmen de Andacollo deposit, which saw some $40M in output in 2010 alone (27,700 oz Au and 34.8kt of Cu). The soon-to-be-acquired prospect is just over five miles…

Continue Reading

ThursdayApr 19, 2012 8:55 am

NeuroMetrix, Inc. (NURO) Files 510(k) for Pain Therapy Device

Yesterday, medical device company NeuroMetrix announced that it has filed a 501(k), also known as a premarket notification, with the Food and Drug Administration for its SENSUS Pain Therapy device. SENSUS is a non-invasive transcutaneous electrical nerve stimulator that is used for pain management and relief. The system is designed to treat chronic intractable pain, such as that associated with diabetic neuropathy. Painful diabetic neuropathy affects as many as 10-20% of people with diabetes, and is a serious and disabling complication of diabetic peripheral neuropathy (DPN). The pain is typically managed pharmacologically; however, many patients remain undertreated. Recent evidence based…

Continue Reading

Market Basics

New to the micro-cap markets?Get answers to your questions about investing in Small-Cap / Micro-Cap Stocks and learn how to protect yourself.

The Basics

Newsletter Publishers

Have an up and coming newsletter and want to be included in our coverage list? Looking to get more coverage and grow subscriptions? Register for coverage.

Register

Public Companies

Are you a Small-Cap / Micro-Cap company looking for coverage? We'd love to hear from you. Fill out our quick contact form or send us a text.

Get Covered